Latest keratoconus Stories
Singapore, Mar 31, 2011 - (ACN Newswire) - At The Eye & Cornea Transplant Centre (TECTC), a subsidiary of Singapore Medical Group, a 39 year-old Taiwanese patient suffering from severe blinding conditions was the first person in Singapore to undergo a complex surgery involving a Boston Keratoprosthesis (Boston KPro) surgery together with ocular surface reconstruction with an amniotic membrane.
ALEXANDRIA, Va., March 29, 2011 /PRNewswire/ -- Oxford Finance Corporation (Oxford), a subsidiary of Sumitomo Corporation, today announced that it closed a $5 million round of debt financing for SynergEyes, Inc.
MCHENRY, Ill., March 29, 2011 /PRNewswire/ -- A potentially blinding disease called keratoconus may now be stopped and even reversed with a new process applying vitamin B2 eye drops and low-dose ultraviolet light to the diseased eye.
For patients with keratoconus and other corneal irregularities, a local eye care center offers a promising new contact lens for improved vision and comfort. Monroe Township, NJ (PRWEB) March 5, 2011 A local ophthalmology and optometry practice has become one of the first in the area to offer an innovative new treatment for keratoconus and other corneal irregularities.
New surgical strategies use a single donor cornea to help two patients with different cornea diseases.
German researcher Claus Cursiefen, MD, also affiliated with Harvard School of Medicine, reports good results with a new surgical strategy that uses a single donor cornea to help two patients with differing corneal diseases.
CARLSBAD, Calif., Dec. 21, 2010 /PRNewswire/ -- This holiday season patients are receiving the life-changing gift of clear and comfortable vision thanks to the Sharing Vision Grant Program sponsored by SynergEyes, Inc.
CARLSBAD, Calif., Sept.
BEVERLY HILLS, Calif., Sept. 22 /PRNewswire/ -- After ten years of dedication to developing new, innovative treatments to help patients with Keratoconus, a degenerative eye disease that affects millions of people worldwide and can cause severe loss of vision, Dr. Brian S.
The Cornea and Laser Eye Institute, with Principal Investigator, Peter S. Hersh M.D., is conducting a research study to study the safety and effectiveness of corneal collagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin in patients with progressive keratoconus and corneal ectasia.